Superoxide production after acute and chronic treatment with methylphenidate in young and adult rats

Neuroscience Letters

Volumn 465, Issue 1, 2009, Pages 95-98

  Gomes, Karin M ^a   Inácio, Cecília G ^a   Valvassori, Samira S ^a   Réus, Gislaine Z ^a   Boeck, Carina R ^a   Dal Pizzol, Felipe ^b   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina   (Brazil)

Author keywords

Attention deficit hyperactivity disorder; Methylphenidate; Oxidative stress; Superoxide

Indexed keywords

METHYLPHENIDATE; SUPEROXIDE;

ACUTE DRUG ADMINISTRATION; ADULT ANIMAL; ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE COMPARISON; HIPPOCAMPUS; JUVENILE ANIMAL; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SUBMITOCHONDRIAL PARTICLE;

AGING; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBELLUM; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; MALE; METHYLPHENIDATE; MITOCHONDRIA; RATS; RATS, WISTAR; SUPEROXIDES;

EID: 70349213202     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.08.060     Document Type: Article

References (42)

1. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci. Biobehav. Rev. 27 (2004) 3-18
2. Andersen S.L. Stimulants and the developing brain. Trends Pharmacol. Sci. 26 (2005) 237-243
3. Aspide R., Fresiello A., Filippis G., Gironi Carnevale U.A., and Sadile A.G. Non-selective attention in a rat model of hyperactivity and attention deficit: subchronic methylphenidate and nitric oxide synthesis inhibitor treatment 24 (2000) 59-71
4. Biederman J., Spencer T., and T. Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 7 (2004) 77-97
5. Bozzy Y., and Borreli E. Dopamine in neurotoxicity and neuroprotection: what do D2 rececptors have to do with it?. Trends Neurosci. 29 (2006) 167-174
6. Bymaster F.P., Katner J.S., Nelson D.L., Hemrick-Luecke S.K., Threlkeld P.G., Heiligenstein J.H., Morin M.S., Gehlert D.R., and Perry K.W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27 (2000) 699-711
7. Connor D.F. Preschool attention deficit hyperactivity disorder a review of prevalence, diagnosis, neurobiology, and stimulant treatment. J. Dev. Behav. Pediatr. 23 (2002) S1-S9
8. Di Ciano P., Couty A., Depoortere R.Y., Egilmez Y., Lane J.D., Emmett-Oglesby M.W., Lepiane F.G., Phillips A.G., and Blaha C.D. Comparison of changes in extracellular dopamine concentrations in the nucleus accumbens during intravenous self-administration of cocaine or d-amphetamine. Behav. Pharmacol. 6 (1995) 311-322
9. Diaz H.R., Kolb B., and Forssberg H. Can a therapeutic dose of amphetamine during pre-adolescence modify the pattern of synaptic organization in the brain?. Eur. J. Neurosci. 18 (2003) 3394-3399
10. Dietrich J., Mangeol A., Revel M., Burgun C., Aunis D., and Zwiller J. Acute or repeated cocaine administration generates reactive oxygen species and induces antioxidant enzyme activity in dopaminergic rat brain structures. Neuropharmacology (2005) 965-974
11. Fagundes A.O., Rezin G.T., Zanette F., Grandi E., Assis L., Dal-Pizzol F., Qevedo J., and Streck E. Chronic administration of methylphenidate actives mitochondrial respiratory chain in brain of young rats. Int. J. Dev. Neurosci. 25 1 (2006) 47-51
12. Fleckenstein A.E., and Hanson G.R. Impact of psychostimulants on vesicular monoamine transporter function. Eur. J. Pharmacol. 479 (2003) 283-289
13. Fleckenstein A.E., Volz T.J., and Hanson G.R. Psychostimulant-induced alterations in vesicular monoamine transporter-2 function. Neuropharmacology 56 (2009) 133-138
14. Fukami G., Hashimoto K., Koike K., Okamura N., Shimizu E., and Iyo M. Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res. (2004) 90-95
15. Gatley S.J., Dongfeng P., Ruoyan C., Gaurav C., and Yu-Shin D. Affinities of methylphenidate derivates for dopamine, norepinephrine and serotonin transporters. Life Sci. 58 (1996) 231-239
16. Gomes K.M., Petronilho F.C., Mantovani M., Garbelotto T., Boeck C.R., Dal-Pizzol F., and Quevedo J. Antioxidant enzyme activities following acute or chronic methylphenidate treatment in young rats. Neurochem. Res. 33 6 (2008) 1024-1027
17. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol. Pharmacol. 14 (1978) 633-643
18. Halliwell B., and Gutteridge M.C. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219 (1984) 1-14
19. Halliwell B., and Gutteridge M.C. Free Radicals in Biology and Medicine. 3rd ed. (1999), Oxford, London
20. Hastings T.G., Lewis D.A., and Zigmond M.J. Role of oxidation in the neurotoxic effects of intrastrial dopamine injections. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 1956-1961
21. Husson I., Mesplés B., Medja F., Leroux P., Kosofsky B., and Gressens P. Methylphenidate and MK-801, an N-methyl-d-aspartate receptor antagonist: shared biological properties. Neuroscience 125 (2004) 163-170
22. Ikai Y., Takad M., Shinonaga Y., and Mizuno N. Dopaminergic and non-dopaminergic neurons in the ventral tegmental area of the rat project, respectively, to the cerebellar cortex and deep cerebellar nuclei. Neuroscience 51 (1992) 719-128
23. Ikai Y., Takada M., and Mizuno N. Single neurons in the ventral tegmental area that project to both the central and cerebellar cortical areas by way of axon collaterals. Neuroscience 61 (1994) 925-934
24. A.C. Issy, C. Salum, E.A. Del Bel, Nitric oxide modulation of methylphenidate-induced disruption of prepulse inhibition in Swiss mice. Behav. Brain Res., in press, doi:10.1016/j.bbr.2009.08.003.
25. Itzhak Y., and Ali S.F. Role of nitrergic system in behavioral and neurotoxic effects of amphetamine analogs. Pharmacol. Ther. 109 (2006) 246-262
26. Kalivas P.W., and Stewart J. Dopamine transmission in the initiation and expression of drug and induced sensitization of motor activity. Brain Res. Rev. 16 (1999) 223-244
27. Kuczenski R., and Segal D.S. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine comparison with amphetamine. J. Neurochem. 68 (1997) 2032-2037
28. Lindow M.S., Bozian D., and Song Z. Cocaine effects cerebral neocortical cytoarchitecture in primates only if administered during neocortical neurogenesis. Dev. Brain Res. 128 (2001) 45-52
29. Madras K.B., Miller G.M., and Fischman A.J. The dopamine transporter and attention-deficit/hyperactivity disorder. Biol. Psychiatry 57 11 (2005) 1397-1409
30. Martins M.R., Reinke A., Petronilho F.C., Gomes K.M., Dal-Pizzol F., and Quevedo J. Methylphenidate treatment induces oxidative stress in early developmental rat brain. Brain Res. 1078 (2006) 189-197
31. Melchitzsky D.S., and Lewis D.A. Tyrosine hydrolase and dopamine transporter immunoreactive axons in the primate cerebellum: evidence for a lobular and laminar specific dopamine innervation. Neuropsychopharmacology 22 (2000) 466-472
32. Pedroso J.J., Carreras M.C., Lisdero C., Riobo N., Schopfer F., and Boveris A. Nitric oxide inhibits electron transfers and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch. Biochem. Biophys. 328 (1996) 35-92
33. Pierce R.C., and Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Rev. 25 (1997) 192-216
34. Radi R., Cassina A., Hodara R., Quijano C., and Castro L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med. 33 (2002) 1451-1464
35. Riddle E.L., Hanson G.R., and Fleckenstein A.E. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. Eur. J. Pharmacol. 571 1 (2007) 25-28
36. Robinson T.E., and Becker J.B. Enduring changes in brain and behaviour produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 396 (1986) 157-198
37. Robinson T.E., and Kolb B. Alterations in the morphology of dentrites and dentritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur. J. Neurosci. 11 (1999) 1598-1604
38. Rowland S.A., Lesesne C.A., and Abramowitz A.J. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment. Retard. Dev. Disabil. Res. Rev. 8 (2002) 162-170
39. Saunders C., Ferrer J.V., Shi L., Chen J., Merril G., Lamb M.E., Leeb-Lundberg L.M.F., Carvelli L., Javitch J.A., and Galli A. Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6850-6855
40. Shaffer D. Attention deficit hyperactivity disorder in adults. Am. J. Psychiatry 151 (1994) 633-638
41. Volkow N.D., Yu-Shin D., Fowler J.S., Wang J., Logan J., Gatley J.S., Dewey S., Ashby C., Liebermann J., Hitzemann R., and Wolf A.P. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch. Gen. Psychiatry 52 (1995) 456-463
42. Yatin S.M., Miller G.M., and Madras B.K. Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation. J. Neurosci. 143 (2005) 69-78